SyneuRx

SyneuRx is a Taiwan-based clinical-stage biopharmaceutical company focused on novel therapeutics for central nervous system disorders and, more recently, antiviral indications. Its lead program is NaBen, an oral D-amino acid oxidase inhibitor being developed as an add-on treatment for schizophrenia, including treatment-resistant patients receiving clozapine. The company has also advanced Pentarlandir, an oral antiviral candidate for early COVID-19 and influenza. SyneuRx is publicly traded in Taiwan and operates from the Greater China region with clinical development activities extending into the United States. Overall, the company is best characterized as a CNS-focused small-molecule developer with late-stage schizophrenia assets and a smaller antiviral program.